%0 Journal Article
%A Macher-Goeppinger, Stephan
%A Keith, Martina
%A Endris, Volker
%A Penzel, Roland
%A Tagscherer, Katrin
%A Pahernik, Sascha
%A Hohenfellner, Markus
%A Gardner, Humphrey
%A Grüllich, Carsten
%A Schirmacher, Peter
%A Roth, Wilfried
%T MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker.
%J OncoTarget
%V 8
%N 1
%@ 1949-2553
%C [S.l.]
%I Impact Journals LLC
%M DKFZ-2017-00062
%P 1046-1057
%D 2017
%X Multiple targeted therapy for advanced clear-cell renal cell carcinoma (RCC) has substantially improved patient outcome, but complete remission is uncommon and many tumors eventually develop resistance. Mechanistic, preclinical, and early clinical data highlight c-Met / hepatocyte growth factor receptor as a promising target for RCC therapeutic agents.We have examined MET expression, frequency of MET gene copy gains and MET gene mutation in a large, hospital-based series of renal cell carcinomas with long-term follow-up information.Out of a total of 572 clear-cell RCC, only 17
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:27894094
%R 10.18632/oncotarget.13540
%U https://inrepo02.dkfz.de/record/119276